Drugs / Olaptesed pegol
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04121455 | Sep 2019 → Dec 2028 expected | glioblastoma | TME Pharma AG | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03168139 | Apr 2017 → Mar 2020 | colorectal cancer, malignant pancreatic neoplasm | TME Pharma AG | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04901741 | Jan 2026 → Mar 2028 expected | malignant pancreatic neoplasm | TME Pharma AG | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Olaptesed pegol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04901741 ↗ |
| Known as | NOX-A12 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594485 ↗ |
| Action | Inhibit | “inactivation of CXCL12 by olaptesed pegol” NCT03168139 ↗ |
| Route | Intravenous | “Olaptesed pegol continuous i.v. administration” NCT04121455 ↗ |
| Target | CXCL12 | “Olaptesed pegol (NOX-A12) targets a key chemokine in the tumor microenvironment, CXCL12” NCT03168139 ↗ |